Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-28
2006-11-28
Epperson, Jon (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255040, C546S184000, C546S205000, C546S239000, C568S659000, C562S405000, C562S468000, C544S358000, C544S396000
Reexamination Certificate
active
07141573
ABSTRACT:
One aspect of the present invention relates to polypharmacophoric compounds. In certain embodiments, the polyphamacophore compounds comprise individual pharmacophore units selected from the group consisting of D-1 agonists, D-2 agonists, D-3 agonists, D-4 agonists, irreversible monoamine inhibitors, reversible monoamine inhibitors, monoamine transporter inhibitors, COMT inhibitors, MAO inhibitors, and dopamine transporter inhibitors. Moreover, the present invention also relates to combinatorial libraries of polypharmacophoric compounds. Another aspect of the present invention relates to the use of a polypharmacophoric compound in a method of treating a mammal in need thereof. For example, a polypharmacophoric compound of the present invention may be used in a method of treating a mammal afflicted with Alzheimer's Disease, Huntington's Disease, depression, attention deficit disorder, autism, obesity, or inflammation.
REFERENCES:
patent: 4202896 (1980-05-01), Gootjes
patent: 4265894 (1981-05-01), Gootjes
patent: 4634792 (1987-01-01), Zanno et al.
patent: 5208260 (1993-05-01), Cordi et al.
patent: 5369113 (1994-11-01), Moldt et al.
patent: 5733756 (1998-03-01), Zeitlin et al.
patent: 0 263 502 (1988-04-01), None
patent: 0 315 519 (1989-05-01), None
patent: 0 417 803 (1991-03-01), None
patent: WO 98/00398 (1998-01-01), None
patent: WO 99/61055 (1999-12-01), None
Solomons, T. W. G. Organic Chemistry Fifth Edition. New York: John Wiley and Sons. 1992, pp. 796-797.
Silverman, R. B. The Organic Chemistry of Drug Design and Drug Action. New York: Academic Press, Inc. 1992.
Dutta, A. K.; Coffey, L. L.; Reith, M. E. A. “Potent and Selective Ligands for the Dopamine Transporter (DAT): Structure-Activity Relationship Studies of Novel 4-[2-(Diphenylmethoxy)ethyl]-1-(3-phenylpropyl)piperidine Analogues” J. Med. Chem. 1998, 41, 699.
Mewshaw et al.; “New Generation Dopaminergic Agents 1. Discovery of a Novel Scaffold Which Embraces the D2Agonist Pharmacophore. Structure- Activity Relationships of a Series of 2-(Aminomethyl ) Chromans”, J. Med. Chem. 40: 4235-4256, (1997).
Jacoby et al.; “A Structural Rationale for the Design of Water Soluble Peptide-Derived Neurokinin-1 Antagonists”, J. Recept. Signal Transduction Res. 17(6):855-873, (1997).
International Search Report Completed on Jul. 25, 2001, and mailed on Aug. 8, 2001.
Babich John W.
Hanson Robert N.
Epperson Jon
Ewing James F.
Molecular Insight Pharmaceuticals, Inc.
Morency Michel
LandOfFree
Polypharmacophoric agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypharmacophoric agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypharmacophoric agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3673123